# MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Source: https://onco.cc/trials/nct05655312/  
OnCo record `nct05655312` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Nivolumab in melanoma, run by Perspective Therapeutics, now recruiting.

## Summary

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma is a phase 1/2 interventional study registered as NCT05655312 by Perspective Therapeutics, with 300 participants planned, started 2023-06-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: [203Pb]VMT01, [212Pb]VMT01, Nivolumab. Conditions listed: Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05655312
- Phase: 1/2
- Setting: A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Finding and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma
- Sponsor: Perspective Therapeutics
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT05655312: https://clinicaltrials.gov/study/NCT05655312

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Perspective Therapeutics](https://onco.cc/companies/perspective-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05655312.json